Novel therapeutic approaches in the treatment of Multiple Myeloma

Last Modified: April 28, 2002

Share article


Conference Dates: September 24, 2002
Conference Location: University of Pennsylvania, Philadelphia, Pennsylvania, USA


Sponsoring Group: University of Pennsylvania and the Multiple Myeloma Research Foundation

Topics Covered:

  • thalidomide
  • transplantation
  • prognostic indicators
  • bisphosphonates
  • novel therapies

Conference Objectives: to learn about the latest therapies available in the treatment of Multiple Myeloma

Who Should Attend: hematologists/oncologists, oncology nurses, patients/families

Conference Agenda:

  • Dr Stadtmauer
  • Dr Greipp
  • Dr Roodman
  • Dr Richardson

Registration Information: For Professionals: CME office, Dian Prahl 215-898-8006. For patients: Sarah Davis, Multiple Myeloma Research Foundation, 203-972-1250

Conference Fees: mds $75 rns $50 patients free

Continuing Education: Yes

Miscellany: professional program is 8-1 and patient program is 2-7


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Nov 21, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More